Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Corporation stock logo
GERN
Geron
$1.51
-2.6%
$1.41
$1.17
$5.06
$961.75M0.6911.20 million shs10.76 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.92
-3.0%
$5.55
$3.81
$29.30
$453.51M1.841.24 million shs3.16 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.29
$1.35
$1.19
$2.04
$1.02B1.393.87 million shs14.29 million shs
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$24.05
-2.3%
$24.36
$18.35
$35.00
$287.81M0.9432,853 shs142,227 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Corporation stock logo
GERN
Geron
0.00%0.00%+2.03%-17.03%-66.37%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%-2.19%+25.19%-50.85%-79.41%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-3.01%+1.57%-28.33%+2.38%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
0.00%+0.84%-4.22%+15.18%+7.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Geron Corporation stock logo
GERN
Geron
3.1825 of 5 stars
3.42.00.01.31.51.70.6
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
4.0545 of 5 stars
4.11.00.04.12.11.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.2738 of 5 stars
3.43.00.04.40.05.00.6
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
3.9739 of 5 stars
3.52.00.03.01.83.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Corporation stock logo
GERN
Geron
2.78
Moderate Buy$5.06235.26% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.13
Hold$14.38192.37% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75113.18% Upside
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
3.00
Buy$69.50188.98% Upside

Current Analyst Ratings Breakdown

Latest XOMA, OPK, GERN, and MYGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00
5/21/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/15/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/8/2025
Geron Corporation stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
5/8/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$18.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $8.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Corporation stock logo
GERN
Geron
$76.99M12.49N/AN/A$0.46 per share3.28
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$837.60M0.54$1.00 per share4.92$7.70 per share0.64
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.43$0.07 per share18.75$2.00 per share0.65
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$28.49M10.10N/AN/A$6.95 per share3.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Corporation stock logo
GERN
Geron
-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)

Latest XOMA, OPK, GERN, and MYGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/7/2025Q1 2025
Geron Corporation stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
5/6/2025Q1 2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Corporation stock logo
GERN
Geron
0.44
7.87
6.97
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.08
1.90
1.71
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1.18
5.54
5.54

Institutional Ownership

CompanyInstitutional Ownership
Geron Corporation stock logo
GERN
Geron
73.71%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
95.92%

Insider Ownership

CompanyInsider Ownership
Geron Corporation stock logo
GERN
Geron
7.42%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.40%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Corporation stock logo
GERN
Geron
70636.92 million589.66 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70092.18 million89.97 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1011.97 million10.88 millionOptionable

Recent News About These Companies

XOMA Royalty Reports Strong Q1 2025 Results
XOMA Royalty: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Geron stock logo

Geron NASDAQ:GERN

$1.51 -0.04 (-2.58%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.52 +0.00 (+0.33%)
As of 06/20/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$4.92 -0.15 (-2.96%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$4.74 -0.19 (-3.76%)
As of 06/20/2025 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.29 0.00 (0.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.30 +0.01 (+0.47%)
As of 06/20/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

XOMA Royalty stock logo

XOMA Royalty NASDAQ:XOMA

$24.05 -0.57 (-2.32%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$23.94 -0.12 (-0.48%)
As of 06/20/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.